Carla Casulo, MD, discusses recent research for new frontline options for patients with newly diagnosed follicular lymphoma.
Carla Casulo, MD, associate professor in the department of medicine at the University of Rochester Medical Center, discusses recent research for new frontline options for patients with newly diagnosed follicular lymphoma (FL).
A large randomized study looked at frontline treatment with the combination lenalidomide (Revlimid) plus rituximab (Rituxan) compared to standard chemotherapy. The study aimed to establish non-inferiority, but it was found that the 2 regimens were not dramatically different, says Casulo.
Behind the FDA Approval of Liso-cel for Relapsed/Refractory CLL/SLL
March 15th 2024In an interview with Targeted Oncology, Tanya Siddiqi, MD, discussed the rationale behind the TRANSCEND CLL 004 study supporting the FDA approval of lisocabtagene maraleucel in chronic lymphocytic leukemia or small lymphocytic lymphoma.
Read More